2021
Genetic testing documentation in survivorship care plans in patients with breast cancer.
Kaur K, Shinde N, Klemanski D, Xu M, Aeilts A, Lustberg M, Jeter J. Genetic testing documentation in survivorship care plans in patients with breast cancer. Journal Of Clinical Oncology 2021, 39: e24110-e24110. DOI: 10.1200/jco.2021.39.15_suppl.e24110.Peer-Reviewed Original ResearchSurvivorship care plansGenetic testing resultsSCP templatesGenetic testingBreast cancerCare plansResult groupGermline mutationsRetrospective chart reviewBreast cancer patientsTest result groupOncology treatment teamNon-Hispanic whitesExtent of documentationCancer genetic testingGenetic counselorsSurvivorship visitChart reviewMedian ageCancer survivorsCancer patientsResult categoriesInvolved genesHereditary predispositionTreatment team
2016
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair
Villalona-Calero M, Duan W, Zhao W, Shilo K, Schaaf L, Thurmond J, Westman J, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. Journal Of The National Cancer Institute 2016, 108: djv437. PMID: 26848151, PMCID: PMC4948564, DOI: 10.1093/jnci/djv437.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesDiarrheaDrug Administration ScheduleFanconi AnemiaFatigueFeasibility StudiesFemaleGenes, BRCA1Genes, BRCA2Germ-Line MutationHumansMaleMiddle AgedMitomycinNeoplasmsPedigreePoly(ADP-ribose) Polymerase InhibitorsRecombinational DNA RepairThrombocytopeniaConceptsPatient tumorsPARP inhibitorsFunctional deficiencySafety/feasibilityDose-escalation trialBRCA germline mutationsCancer patient tumorsClinical Laboratory Improvement AmendmentsArchival tumor materialCombination armEscalation trialAntitumor responseClinical benefitSevere toxicityTumor specimensPatientsDose levelsSolid tumorsGermline analysisGermline alterationsTumor materialTumorsVeliparibBRCA genesGermline mutations